A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine

HIGHLIGHTS

SUMMARY

    Outcomes Measures included but not limited to: headache/migraine days, headache-related quality of life including Headache Impact Test 6 (HIT-6), Migraine Disability Assessment Score (MIDAS), and migraine specific quality of life, acute treatment use, headache intensity and duration, health service activity, days lost from usual activities, incremental cost-effectiveness ratios (ICER) (e_g, cost per disability-adjusted life year averted, cost per quality-adjusted life year gained). All studies originated from high-income countries, mainly countries in European Union (n=5), including two each in the UK and the United_States. Four reports were . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?